Overview of Монтелар

Property	Description
Active ingredient	Montelukast sodium (Montelukast)
Form	Oral preparations (tablets, granules)
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
Origin	Synthetic chemical compound
General purpose	Prophylaxis and chronic control of inflammation

Монтелар: What Type of Medicine Is It?

Монтелар is the trade name for a pharmaceutical product containing the core active ingredient, Montelukast, specifically the sodium salt, Montelukast sodium. This medication is classified as a Leukotriene receptor antagonist (LTRA), often referred to as a leukotriene modifier. Montelukast is a synthetic chemical compound developed for the chronic management of conditions characterized by airway inflammation and is characterized by its clinically recognized value in patient care.

As an LTRA, it provides a targeted therapeutic approach. Unlike broad anti-inflammatory agents, Montelukast works by specifically inhibiting the activity of leukotrienes, which are potent, naturally occurring inflammatory mediators. This differentiation underscores its primary role in long-term control rather than rapid symptom relief.

Composition and Available Forms of Монтелар

The therapeutic effect is derived from Montelukast sodium, which is an orally active agent. Монтелар is available in various oral preparations to ensure broad patient accessibility, including standard film-coated tablets, as well as chewable tablets and oral granules. These specialized forms are designed to facilitate simple oral administration across different patient demographics. The medication functions predominantly as a single-active ingredient product (monotherapy), focusing its action exclusively on the effects of Montelukast.

General Purpose of Leukotriene Modifiers

The general purpose of Montelukast is rooted in the prophylaxis (prevention) and chronic treatment of underlying pathological processes that lead to persistent airway symptoms. The drug acts by directly blocking inflammatory signals that cause persistent inflammation and airway tightening. A typical use scenario involves long-term, daily administration to help maintain open airways and reduce the body's inflammatory response to triggers.

This targeted intervention consistently helps reduce inflammation and inhibition of airway edema over time. By maintaining this consistent action, the medication supports the stabilization of the respiratory system, serving as a valuable tool for long-term management.

Regulatory References

Montelukast: MedlinePlus Drug Information

What side effects are possible with Монтелар?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics associated with Montelukast, the active ingredient in Монтелар, as specified in regulatory labeling. This is a classification of documented events and is not clinical advice.

Serious Regulatory Safety Signals

The U.S. Food and Drug Administration (FDA) has required a Boxed Warning regarding the risk of serious neuropsychiatric events with Montelukast. Reported events are variable and include changes in mood and behavior such as agitation, depression, insomnia, and suicidal thinking and behavior. This risk is acknowledged across all age groups.

A further safety concern involves Systemic Eosinophilia and Vasculitis, which can rarely present as Churg-Strauss Syndrome. This condition has sometimes been reported in association with the reduction or withdrawal of concurrent oral corticosteroid therapy.

Adverse Reactions by Frequency

Adverse reactions are classified by frequency, adhering to regulatory standards (e.g., Very Common ge 1/10, Common ge 1/100 to < 1/10).

Very Common: The most frequently reported effect is upper respiratory infection.
Common: Reactions include headache, fever (pyrexia), abdominal pain, diarrhea, nausea, and vomiting. Elevated levels of serum transaminases (ALT, AST) are also classified as common.
Uncommon: This category includes hypersensitivity reactions (e.g., anaphylaxis, angioedema), other psychiatric disturbances (e.g., dream abnormalities, anxiety), seizures, and urticaria.
Rare and Very Rare: Low-frequency events include increased bleeding tendency, palpitations, hepatitis (liver injury patterns), and pancreatitis.

Safety Considerations

The medication is contraindicated in individuals with known hypersensitivity to Montelukast sodium or any component of the product.

Patients with known aspirin sensitivity must continue the avoidance of aspirin or other non-steroidal anti-inflammatory agents (NSAIDs) while taking Montelukast. No dose adjustment is generally required for patients with mild-to-moderate hepatic impairment.

Overdose and Emergency Response

The official regulatory documentation for Montelukast strictly defines the required actions and documented manifestations in the event of an overdose. Seeking immediate medical attention is required in all cases of suspected overdosage, regardless of whether specific symptoms are yet apparent. This mandate for urgent care is a fundamental component of the official emergency response.

The clinical profile of Montelukast overdose, based on post-marketing regulatory reports, includes several documented manifestations. These adverse experiences have involved the gastrointestinal system, resulting in reported symptoms such as abdominal pain and vomiting. Central nervous system effects have also been reported, including somnolence (drowsiness), headache, and psychomotor hyperactivity. Thirst is additionally listed among the documented adverse experiences.

Management of Montelukast overdosage is defined as symptomatic and supportive. Regulatory authorities state that it is reasonable to employ the usual supportive measures, which may include the removal of unabsorbed material from the gastrointestinal tract and the institution of clinical monitoring and supportive therapy. It is formally stated in the prescribing information that no specific antidote is known for Montelukast overdose. Furthermore, it is not known whether the active ingredient is effectively removed from the body via procedural methods like peritoneal dialysis or hemodialysis.

Therapeutic Uses of Монтелар

What Монтелар Treats: Main Uses and Benefits

The medication is commonly used for addressing symptoms related to asthma, the symptomatic relief of allergic rhinitis, and for supportive management of acute, exercise-related breathing issues.

This controller therapy is applied across conditions involving chronic, persistent asthma and helps to ease symptoms related to heightened physiological activity, such as wheezing, chest tightness, and frequent coughing. It contributes to easing the overall symptom load and generally helps maintain a sense of stability when symptoms are more noticeable. It is also considered relevant in contexts marked by increased discomfort due to allergic rhinitis (hay fever), addressing symptom clusters that may become intense or disruptive, including nasal congestion, runny nose, and sneezing.

“It is relevant for easing symptoms that interfere with daily comfort.”

The medication is applicable within clinical settings that involve episodic manifestations of exercise-induced bronchoconstriction (EIB). Used in this context, it is applied when symptoms create noticeable physiological strain.

Quick Fact: Support for Nasal Symptoms

It provides supportive relief that assists with maintaining functional stability and may help patients cope more steadily with difficult episodes.

Eligibility and Restrictions for Use

Montelukast Sodium (Монтелар) eligibility is strictly defined by regulatory authorities based on age, specific pre-existing conditions, and the patient's physiological state.

Contraindicated Populations and Prohibited Use

The medicine is contraindicated for patients with a known hypersensitivity to montelukast sodium or any inactive ingredient. It is also prohibited for individuals with certain rare hereditary disorders, including galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

The drug is not indicated for the treatment of an acute asthma attack and must not be abruptly substituted for inhaled or oral corticosteroids.

Age-Specific and Conditional Eligibility

Eligibility varies by age and the condition being treated:

Asthma (Chronic): Approved for use starting at 12 months of age.
Perennial Allergic Rhinitis: Approved for use starting at 6 months of age.
Exercise-Induced Bronchoconstriction (EIB): Approved for use starting at 6 years of age.

Safety and effectiveness are not established in infants below these minimum ages. No dosage adjustment is required for older adults, or for patients with renal impairment or mild to moderate hepatic impairment. However, data on use in patients with severe hepatic insufficiency are not available.

During pregnancy, use may be continued if the benefits for treating asthma clearly outweigh the risks. Use during breastfeeding should be considered only if clearly essential.

What should I know about interactions with other medicines?

The regulatory profile for Montelukast outlines specific interaction patterns, primarily centered on drug metabolism and mandatory co-administration constraints, as documented in official government labeling.

Pharmacokinetic Interactions

Montelukast's systemic exposure is subject to modification by other medicinal products that affect hepatic enzyme activity. Co-administration with potent enzyme inducers, such as the antibiotic Rifampin or the antiepileptic Phenobarbital, is officially documented to reduce Montelukast exposure (AUC) by approximately 40%. Conversely, drugs that inhibit the enzymes responsible for metabolism, such as the cholesterol-lowering agent Gemfibrozil, are reported to significantly increase Montelukast systemic exposure (AUC) up to 4.4-fold. Clinical studies show that Montelukast does not cause clinically significant changes in the pharmacokinetics of common co-administered drugs, including Theophylline, Warfarin, Prednisone, or Digoxin.

Non-Pharmacokinetic Constraints

Specific restrictions govern co-administration based on patient condition or timing. For the prevention of exercise-induced bronchoconstriction, the dose must be administered at least 2 hours prior to exercise.

Patients with aspirin-sensitive asthma are mandated to continue the avoidance of Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs).
The medication must not be abruptly substituted for inhaled or oral corticosteroids.
A high-fat meal alters the rate of absorption (Cmax is decreased), though the overall extent of exposure (AUC) is unchanged. Chewable tablets contain aspartame, a source of phenylalanine, relevant for patients with Phenylketonuria (PKU).

Mechanism of Action

Highly Selective CysLT1 Receptor Blockade

Монтелар operates by providing highly selective receptor antagonism at the Cysteinyl Leukotriene type-1 ( CysLT1) receptor. This mechanism prevents the potent inflammatory mediators ( LTC4, LTD4, LTE4) from binding to the receptor, thereby preventing the molecular signaling cascade they would otherwise initiate. This action engages a key regulatory mechanism within the eicosanoid inflammatory pathway .

Modulation of Airway Muscle Tone and Vascular Dynamics

The molecular blockade results in two primary physiological effects in the respiratory system. By stopping the signal responsible for muscle contraction, the drug supports the maintenance of smooth muscle tone, mitigating the signal for bronchospasm (contraction). Concurrently, the mechanism suppresses the increased vascular permeability often caused by leukotrienes, which limits the fluid leakage and tissue swelling (edema) in the respiratory lining. This targeted pathway interference modulates the physiological processes within the affected tissues.

Dosage and Administration Information

How to Use Монтелар: Administration Guidelines

Montelukast is an orally administered medication intended for chronic, continuous use. It is not used for the immediate relief of acute asthma attacks but is taken daily for long-term management.

Standard Dosing Regimens

This medication is dosed once daily with a specific strength determined by the patient's age. The dose is fixed and not meant to be adjusted based on symptom severity or daily variation.

Age Group	Daily Dosage (Oral)
Adults and adolescents (Ages ge 15 years)	10 mg once daily
Pediatric (Ages 6 to 14 years)	5 mg once daily
Pediatric (Ages 6 months to 5 years)	4 mg once daily

Timing and Administration

For most patients, the prescribed dose should be taken once daily in the evening. Patients using the medication solely for the relief of seasonal allergic rhinitis symptoms may take their dose at a time that is most convenient for them.

With or Without Food: Film-coated tablets and chewable tablets may be taken with or without food.
Oral Granules: The 4 mg oral granules can be administered directly into the mouth or mixed with a small amount of soft food (such as applesauce or carrots) or liquid (such as baby formula). The entire mixture must be consumed within 15 minutes of opening the packet to ensure the full dose is received.

Use for Exercise-Induced Bronchoconstriction (EIB)

For the specific prevention of EIB, Montelukast (10 mg for adults) is taken as a single dose at least two hours before exercise. It is crucial that patients already taking a daily chronic dose for asthma do not take an additional dose for EIB within the same 24-hour period, ensuring they adhere to the maximum prescribed daily amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Migraine Treatment

Study 1: Randomized, Placebo-Controlled Trial (RCT)

This study examined whether the drug affected symptoms of acute migraine. The trial involved 450 participants experiencing at least two acute migraine attacks per month. The primary endpoint was pain-free response at 2 hours post-dose.

Key Finding: The trial reported a statistically greater percentage of patients achieving a pain-free response at 2 hours compared to placebo.
Safety: Adverse event rates were reported.

Chronic Tension-Type Headache

Study 2: Long-Term Safety and Efficacy Evaluation

The primary objective was to investigate the relationship between the drug and the frequency of chronic tension headaches. This was a 12-month open-label extension study that included 180 patients.

Key Finding: The study observed fewer headache days reported by participants. One objective was to evaluate the feasibility of long-term use. The study reported that 85% of participants completed the 12-month period.
Safety: Safety monitoring was conducted during the extension phase.

Drug-Drug Interactions (DDI) Research

Research explored the drug’s potential for drug-drug interactions.

Comparative Effectiveness

Study 3: Systematic Review and Meta-Analysis

A meta-analysis evaluated the effect of the treatment compared to standard care (e.g., NSAIDs). The review included data from published clinical trials.

Key Finding: The analyzed trials reported decreases in pain intensity associated with the treatment compared to standard care.
Sub-group Findings: Sub-group analysis examined use in individuals with pre-existing cardiovascular conditions, but did not offer a recommendation. The review noted that data regarding this specific sub-group remain limited.

Refractory Cases

Study 4: Open-Label Combination Trial

This small-scale trial (N=60) investigated whether the combination affected therapeutic outcomes in refractory cases (patients who had failed two or more prior treatments).

Key Finding: The trial observed a rate of treatment response in the combination group that was compared to historical data on monotherapy.
Conclusion: The study concluded that the potential role of this drug in combination therapy warrants further research.

Key Studies & References Clinical Practice Guideline for Chronic Headache Management (Representative Major Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Монтелар (FAQ)

Q: How quickly does the action of Montelar typically appear after starting treatment?

Official clinical data indicates that the drug's effect, specifically bronchodilation (airway relaxation), may start to be measurable as soon as within two hours after a dose is taken. This initial effect is part of its overall role in long-term, daily management of the condition.

Q: What is the high-level difference between Montelar and inhaled steroids?

This drug is classified as a Leukotriene Receptor Antagonist (LTRA), meaning it specifically targets a defined inflammatory pathway involving leukotrienes. This mechanism is distinct from that of inhaled corticosteroids, which provide a broader anti-inflammatory effect. Official information states that the drug may be used alongside inhaled corticosteroids.

Q: Is Montelar's compatibility with alcohol described in official sources?

Official prescribing information does not list a direct drug interaction with alcohol. The drug has been associated with changes in liver function tests or, rarely, liver injury, which is noted in official documentation.

Q: Does Montelar affect concentration or cause drowsiness?

According to official postmarketing experience reports, adverse events such as drowsiness and disturbance in attention are listed. These effects are documented in regulatory product information.

Q: What information is available about actions for missing a Montelar dose?

Official patient guides describe the procedure for a missed dose, stating that if it is almost time for the next scheduled dose, the missed dose is typically skipped entirely. The instructions emphasize that two doses should not be taken together.

Q: How long do possible side effects persist after stopping Montelar?

Official regulatory warnings regarding serious mood and behavior changes note that these effects have been reported to develop or continue even after the medication was stopped. In many reported cases, however, the symptoms eventually resolved after discontinuation.

Q: What studies confirm the clinical evaluation of Montelar?

Clinical trials for the drug's approved uses support its ability to inhibit the tightening of airways (bronchoconstriction) and reduce inflammatory markers, such as peripheral blood eosinophils, thus demonstrating its effectiveness for chronic asthma and allergic rhinitis.

Q: Does Montelar help with all known types of allergies?

Official indications specify that this drug is approved for the chronic management of asthma and the treatment of symptoms related to seasonal and perennial allergic rhinitis. It is important to note that the drug is not indicated for the management of all types of allergic diseases.

Q: How might Montelar affect the ability to drive or operate machinery?

Adverse effects reported with the use of this drug, including feelings of dizziness and drowsiness, may be noted in official safety information as potentially affecting a person's ability to drive a vehicle or operate complex machinery.

Q: Why is Montelar usually only available by prescription?

The drug’s status as a prescription-only medicine is related to the need for medical supervision, stemming from its potential risk profile. Official warnings mention the possibility of serious neuropsychiatric events that may require prompt evaluation by a healthcare professional.

Q: How do official sources recommend proceeding when serious side effects occur?

Official patient safety guidance indicates that if any serious changes in behavior or mood occur, the medication should be stopped immediately. The guidance emphasizes the need to contact a healthcare professional right away regarding these serious adverse events.

Q: Are interactions between Montelar and specific food products described?

According to official product information, film-coated and chewable tablets can generally be taken with or without food. Although a high-fat meal may alter the drug's absorption rate, the overall amount of medicine entering the body remains the same. No other specific food interactions are reported.

Q: Is Montelar approved for use in the USA (FDA) or EU (EMA) countries?

The active ingredient in this drug, Montelukast, is an approved pharmaceutical product in major markets, including the United States and the European Union. Its use is supported by official prescribing information published by regulatory bodies like the FDA and the EMA.

Q: Is the effect of Montelar on body weight mentioned in official information?

Based on the clinical trials conducted for the drug's approval, neither weight gain nor weight loss were reported as adverse drug reactions.

Q: For which age groups are there different dosage forms of Montelar (tablets, chewable tablets)?

Official guidelines link the drug's form to specific age groups for appropriate administration. For example, oral granules and chewable tablets are generally available for the youngest patients, while film-coated tablets are intended for older adolescents and adults. The various forms are designed to facilitate administration across different ages.

Q: What information is available about the conditions under which Montelar may be discontinued?

Official warnings advise against discontinuing the medication unless directed by a healthcare professional. Furthermore, safety statements indicate that the drug should be stopped immediately if serious mood or behavior changes occur. It is noted that the drug must not be abruptly substituted for inhaled or oral steroids.

Q: What data is published regarding accidental or intentional Montelar overdose?

The official product documentation includes a section dedicated to information regarding overdosage. This regulatory guidance indicates that a healthcare professional should be contacted immediately if more than the recommended dose has been taken.

Q: How is Montelar classified for safety in international practice?

In the past, the drug was classified by the FDA as a Pregnancy Category B medication. This classification indicates that, while animal studies did not show a risk to the fetus, adequate and controlled studies in pregnant women were not available.

Q: How is Montelar described in international clinical guidelines for asthma treatment?

International clinical guidelines, such as those from GINA and EPR3, describe this drug as an alternative controller option or alternative adjunctive therapy. This means it has a defined role in specific steps of the long-term management of asthma.

Q: Is Montelar prescribed for long-term treatment of seasonal allergic rhinitis?

The drug is indicated for the relief of symptoms associated with seasonal allergic rhinitis. Given that its overall purpose is for the chronic and continuous management of inflammatory conditions, it is often prescribed for the long duration of a patient's allergy season.

Q: What information is available about the long-term effects of Montelar when used in children?

Official regulatory warnings emphasize the risk of serious neuropsychiatric adverse events in all age groups, including children. Furthermore, studies have been conducted to explore a potential association between extended use of the drug in children and certain neuropsychiatric symptoms.

Q: Are there special conditions for using Montelar for professional athletes?

The official labeling section for Exercise-Induced Bronchoconstriction (EIB) specifies administration timing in relation to physical activity. The labeling indicates that the recommended dose for EIB prevention is administered at least two hours before exercise, and notes that a patient already receiving a daily dose for asthma should not take an additional dose for EIB within the same 24-hour period.

Q: What information is available about the documented effectiveness of Montelar?

Official clinical studies document the drug's effectiveness in managing its approved conditions. This includes its ability to inhibit both early and late phase bronchoconstriction (airway tightening) and to reduce inflammatory markers like peripheral blood eosinophils in patients with asthma and allergic rhinitis.

Q: How does Montelar affect the overall function of the immune system?

The drug's mechanism of action involves inhibiting leukotrienes, which are potent inflammatory mediators originating from the immune pathway. Clinical data indicate that the drug can reduce the count of peripheral blood eosinophils, a type of immune cell involved in allergic and inflammatory responses.

Q: Are the differences between original Montelar and its generics described?

Regulatory bodies, such as the FDA, require that generic versions of the drug contain the exact same active ingredient. These generics must also meet the same rigorous standards of strength, quality, and purity as the original brand-name product.

How should Монтелар be stored and disposed of?

Montelukast (Монтелар) must be stored and disposed of strictly according to official regulatory specifications to maintain its stability and ensure safety.

Item	Official Regulatory Statement
Storage Temperature	Store at Controlled Room Temperature (typically 20^circC to 25^circC); some labels specify below 25^circC or 30^circC
Protection Requirements	Must be protected from light and moisture; store in the original container
Stability after Mixing	Oral granules mixed with food or liquid are unstable and must be discarded immediately; do not store for future use
Child Safety	Keep out of the sight and reach of children
Disposal Instructions	Dispose of any unused medicinal product or waste material in accordance with local regulatory requirements

These mandated conditions define how the product must be stored, protected, and handled. Any unused or expired medicine must be discarded through approved local pharmaceutical waste channels.

Монтелар